Concepedia

Author

Deborah Hagan

Bristol-Myers Squibb (United States)

Also Known As

D L Hagan, Deborah Hagan, Deborah L. Hagan

9

Publications

1.8K

Citations

9

H-Index

26

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)
DH

About

Deborah Hagan is an author at Bristol-Myers Squibb (United States) specializing in biochemistry, medicine, and diabetes.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

946

2

Biochemistry

4

4

946

3

Diabetes

3

3

821

4

Health Sciences

2

2

277

5

Cell Biology

2

2

277

Deborah Hagan

×

9

Publications

1.8K

Citations

9

H-Index

YearCitations

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl,

Journal of Medicinal Chemistry

2008

612

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

Song‐Ping Han, Deborah Hagan, Joseph R. Taylor,

Diabetes

2008

416

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

Jian Chen, Sandy Williams, Samantha Ho,

Diabetes Therapy

2010

300

Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: A sequestration mechanism in metabolic regulation

Dennis Farrelly, Karen Brown, Aaron Tieman,

Proceedings of the National Academy of Sciences

1999

152

Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators.

Deborah Hagan, Bernadette Kienzle, H Jamil,

Journal of Biological Chemistry

1994

125

Expression of Human Hepatic Glucokinase in Transgenic Mice Liver Results in Decreased Glucose Levels and Reduced Body Weight

Narayanan Hariharan, Dennis Farrelly, Deborah Hagan,

Diabetes

1997

101

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2

Bruce A. Ellsworth, Wei Meng, Manorama M. Patel,

Bioorganic & Medicinal Chemistry Letters

2008

57

Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor

Mark A. Tirmenstein, Thomas Dorr, Evan B. Janovitz,

International Journal of Toxicology

2013

37

Identification of small-molecule protein–protein interaction inhibitors for NKG2D

Aaron A. Thompson, Michael B. Harbut, Pei‐Pei Kung,

Proceedings of the National Academy of Sciences

2023

10

Page 1